With its continued commitment towards advance therapy adoption in intervention cardiology for treating Complex and High-risk Coronary Intervention (CHIP) patients, Boston Scientific has collaborated with Dr Masahisa Yamane, Director of Cardiovascular Division, Sekishinkai Saitama Hospital, Saitama, Japan to proctor workshops in five cities in India — Delhi, Lucknow, Hyderabad, Ahmedabad, and Patna from 3rd to 7th February, 2020. Dr Yamane will be working collaboratively with leading Indian physicians for effective usage of latest innovative technologies for optimal treatment of extremely complex and high-risk angioplasties to ensure better patient outcomes.
The company has therapies available in India which enable medical imaging using ultrasound waves to view inside the target blood vessels in the heart. This can provide the physician with critical information about the diseased area and may aid in selection of optimal treatment plan and stent implantation. Drug Eluting Stents which have extensive clinical evidence in human populations across geographies and globally acknowledged accreditations with optimum drug eluting regimen of three to four months may also provide better outcomes in highly complex angioplasties in the long term for the patients, thereby improving the quality of life.
Manoj Madhavan, Managing Director, Boston Scientific, said, “We at Boston Scientific are dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Collaborative workshops like these conducted on latest technological advancements in the interventional cardiological space would enable a platform for our doctors in India to discuss how technology has aided the journey of CVD treatments, with next generation stents and therapies like Intravascular Ultrasound and Rotational Atherectomy as frontrunners that may aid in treatment of artery blockages and other coronary complexities.”